NCT03578029View on ClinicalTrials.gov

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 22, 2019

Primary Completion Date

September 1, 2021

Study Completion Date

November 23, 2021

Conditions
Junctional Epidermolysis BullosaDystrophic Epidermolysis Bullosa
Interventions
DRUG

RGN-137

It will be applied topically to the appropriate wound once a day for up to 84 days.

DRUG

Placebo

It will be applied topically to the appropriate wound once a day for up to 84 days.

Trial Locations (5)

11203

SUNY Downstate Medical Center, Brooklyn

19104

The Children's Hospital of Philadelphia, Philadelphia

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

60208

Northwestern University, Evanston

78218

Texas Dermatology and Laser Specialists, San Antonio

Sponsors
All Listed Sponsors
lead

Lenus Therapeutics, LLC

INDUSTRY